LLY vs PLX

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Protalix (PLX) maintains significant growth potential following the EU approval of Elfabrio's expanded dosing regimen and the triggered $25.0 million milestone, boosting projected cash to ~$50 million by April 2026. This, coupled with robust 2026 revenue guidance of $78–$83 million, strengthens its strategic market position in rare diseases. However, the FY 2025 TTM net loss of $6.6 million, a cle...